|
<HOME
September 22, 2009: Selexis and Neogenix Oncology enter into research services agreement
Geneva, Switzerland, and Great Neck, New York
http://www.selexis.com/media/news_090922.html
Selexis SA ("Selexis") and Neogenix
Oncology, Inc. ("Neogenix") today
jointly announced a Research Services Agreement for the rapid development
of a high-performance CHO based production cell line expressing an
undisclosed Neogenix antibody. The cell line will be developed by Selexis
scientists utilizing the industry leading Selexis SURE Cell Line
Development™ Platform.
"We are very appreciative to have this opportunity to establish a strong
partnership with the world class scientists at Neogenix as the company
develops innovative therapies for the management of serious and difficult
to treat cancers." said Dr Igor Fisch, CEO and co-founder of Selexis,
SA. "By targeting antigens shown only to be associated with tumor cells, Neogenix is in a unique position with regards to treating cancer, making
this a very special program to us."
"After careful consideration Neogenix chose Selexis for this important
project based on their industry reputation and proven record of
performance in being able to quickly generate production cell lines to
support high demand antibody programs like ours," said Dr. Andrew
Bristol, Vice President of Research and Development of Neogenix.
Neogenix Oncology, Inc. announced last week that the Food and Drug
Administration (FDA) has granted permission for the company to begin a
Phase I trial with its first therapeutic antibody,NPC-1C under its first
IND (Investigational New Drug Application). This first human trial will
evaluate the safety of NPC-1C in patients with late stage pancreatic or
colorectal cancer. The project being undertaken with Selexis will make an
important contribution toward the development and potential
commercialization of this and other potential Neogenix products.
About Selexis
Selexis is a privately held Swiss biotechnology company dedicated to the
development of innovative technologies and expert services that enable
significant improvements in the time, effort, and costs required to
develop and maintain high-performance mammalian cell lines used in the
expression of pharmaceutically relevant proteins (i.e. targets, MAbs,
rProteins). The company's core intellectual property portfolio is based on the
discovery and application of novel DNA based
elements that control the dynamic organization
of chromatin within all mammalian cells - Selexis
Genetic Elements™. Selexis has further developed platforms, to include:
Selexis SUREtech Vectors™, Selexis SUREfection™ Selexis SURE Cell Line
Development™
and Selexis INTEGRA-D2™.
More information
Phone: +41 (0)22 308 93 60
Email: SURE@selexis.com
About Neogenix Oncology, Inc.
Founded in 2004, Neogenix Oncology, Inc., headquartered in Great Neck, NY,
is a research-driven biopharmaceutical company that develops and
commercializes innovative diagnostics and therapeutics for the management
of solid tumors. Neogenix's pipeline is derived in part from the
Hollinshead library of clinically tested vaccines, with the potential to
develop products for a wide range of cancers, including colorectal,
prostate, lung, ovarian, squamous, and others. The company conducts its
research and development work in its laboratories in Great Neck, NY and in
Rockville, MD. For more information, please visit the company's website at
www.neogenixoncology.com
|